According to a national health survey by the Australian Bureau of Statistics, it was found that in the year 2017-2018, almost half of the population of Australia (47.3%) had one or more chronic conditions, which shows an increase from the previous data of (42.2.%) for the year 2007-2008. According to the Centers for Disease Control and Prevention (CDC), 6 in 10 adults in the U.S. have a chronic disease, and 4 in 10 adults have two or more chronic disease
Access Full Report @ https://www.databridgemarketresearch.com/reports/global-lyophilized-injectable-drugs-market
Global Lyophilized Injectable Drugs Market is expected to reach USD 6,791.25 million by 2028 from USD 4,318.00 million in 2020, growing with a substantial CAGR of 6.2% in the forecast period of 2021 to 2028. Chronic diseases are caused due to various risk behaviors such as poor nutrition, excessive alcohol consumption, tobacco use, and lack of physical activity. The increased incidence of chronic diseases raises the demand for the prognosis of such diseases via proper advanced medications, thereby propelling the growth of the global lyophilized injectable drugs market. Many market players are involved in offering the lyophilized injectable drugs products with innovations that pave the way for the growth of the lyophilized injectable drugs market.
The overall rise in the chronic health conditions across the world will drive the market's growth rate
Chronic diseases are caused due to various risk behaviors such as poor nutrition, excessive alcohol consumption, tobacco use, and lack of physical activity. The increased incidence of chronic diseases raises the demand for the prognosis of such diseases via proper advanced medications, thereby propelling the growth of the global lyophilized injectable drugs market. The rising incidence of chronic diseases, including diabetes, cardiovascular diseases, and cancer, is expected to accelerate the demand for lyophilized injectable drugs, among others, to cure these conditions. Thus, the increased incidence rates of chronic diseases are boosting the growth of the market.
Report Scope and Market Segmentation
Report Metric
|
Details
|
Forecast Period
|
2021 to 2028
|
Base Year
|
2020
|
Historic Years
|
2019 (Customizable to 2013 - 2018)
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
Segments Covered
|
Packaging (Vials, Dual-Chamber Syringes, Dual-Chamber Cartridges and Others), Drug Class (Anti-Infective, Antineoplastic, Diuretics, Proton Pump Inhibitor, Anesthetic, Anticoagulant, NSAID’s, Corticosteroids and Others), Form (Powder and Liquid), Indication (Oncology, Autoimmune Diseases, Hormonal Disorders, Respiratory Diseases, Gastrointestinal Disorders, Dermatological Disorders, Ophthalmic Diseases and Others), Route of Administration (Intravenous/Infusion, Intramuscular and Others), End User (Hospital, Clinics, Home Healthcare and Others), Distribution Channel (Direct Tender, Retail Sales and Others)
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
Market Players Covered
|
Affy Pharma Pvt Ltd. (India), Genex Pharma (India), AuroMedics Pharma LLC (U.S.), Astellas Pharma Inc. (U.S.), Pfizer Inc. (U.S.), Viatris Inc. (U.S.), Gilead Sciences, Inc. (U.S.), Cirondrugs (India), Amneal Pharmaceuticals LLC (U.S.), Jubilant Generics Limited (India), Novartis AG (Switzerland), Otsuka America Pharmaceutical, Inc. (U.S.), Zydus Cadila (India), Cipla Inc. (India), Merck Sharp & Dohme Corp. (Germany), Fresenius Kabi (U.S.), Sanofi (France), Celon Laboratories Pvt. Ltd. (India) and Baxter (U.S.) among others.
|
Data Points Covered in the Report
|
In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario the market report curated by the Data Bridge Market Research team includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework
|
Segment Analysis:
Global lyophilized injectable drugs market is categorized into seven notable segments which are based on the packaging, drug class, form, indication, route of administration, end user and distribution channel.
- On the basis of packaging, global lyophilized injectable drugs market is segmented into vials, dual-chamber syringes, dual-chamber cartridges and others. In 2021, vials segment is expected to dominate the lyophilized injectable drugs market with 74.48% market share because most of the lyophilized injectable drugs are packaged in vials, so it is influential as well as growing in the market.
- On the basis of drug class, global lyophilized injectable drugs market is segmented into anti-infectives, antineoplastic, diuretics, proton pump inhibitor, anesthetic, anticoagulant, NSAID’s, corticosteroids and others. In 2021, anti-infectives segment is expected to dominate the lyophilized injectable drugs market with 44.30% market share because of the increased demand for the antibiotics and antiviral drugs across globe.
- On the basis of form, global lyophilized injectable drugs market is segmented into powder and liquid. In 2021, powder segment is expected to dominate the lyophilized injectable drugs market with 93.60% market share because of its easy and safe storage plus transportation across globe.
- On the basis of indication, global lyophilized injectable drugs market is segmented into oncology, autoimmune diseases, hormonal disorders, respiratory diseases, gastrointestinal disorders, dermatological disorders, ophthalmic diseases and others. In 2021, oncology segment is expected to dominate the lyophilized injectable drugs with 48.36% market share because of the availability of increased number of lyophilized injectable drugs for oncology.
- On the basis of route of administration, global lyophilized injectable drugs market is segmented into intravenous/infusion, intramuscular and others. In 2021, intravenous/infusion segment is expected to dominate the lyophilized injectable drugs market with 73.04% market share because of the 100% bioavailability of the drug via this route of administration.
- On the basis of end user, global lyophilized injectable drugs market is segmented into hospital, clinics, home healthcare and others. In 2021, hospital segment is expected to dominate the lyophilized injectable drugs market with 37.83% market share due to the financial capabilities of hospitals to purchase luxurious equipment along with the presence of trained professionals to administer them.
The hospital segment will dominate the end user segment of the lyophilized injectable drugs market
The hospital segment will emerge as the dominating segment end user segment. This is because of the growing number of hospitals especially in the developing economies. Further, growth and expansion of research development services on a global scale will further bolster the growth of this segment.
- On the basis of distribution channel, global lyophilized injectable drugs market is segmented into direct tender, retail sales and others. In 2021, direct tender segment is expected to dominate the lyophilized injectable drugs market with 82.99% market share because most of the service providers buy the lyophilized injectable drugs from manufacturers and it is noticed that revenue from direct sales is higher, so it is influential as well as growing in the market.
The direct tender segment will dominate the distribution channel segment of the lyophilized injectable drugs market
直接投標部分將成為分銷管道的主導部分。這是因為市場上尤其是發展中經濟體的基礎設施開發活動不斷增加。此外，全球化學品和材料行業的成長和擴張將進一步促進該領域的成長。
主要參與者
Data Bridge Market Research 將以下公司視為表面消毒劑市場的參與者：Affy Pharma Pvt Ltd.（印度）、Genex Pharma（印度）、AuroMedics Pharma LLC（美國）、Astellas Pharma Inc.（美國）、Pfizer Inc.（美國）、Viatris Inc.（美國）、Gilead Sciences, Inc.(美國） Limited（印度）、Novartis AG（瑞士）、Otsuka America Pharmaceutical, Inc.（美國）、Zydus Cadila（印度）、Cipla Inc.（印度）、Merck Sharp & Dohme Corp.（德國）、Fresenius Kabi（美國）、Sanofi（法國）、Celon Laboratories Pvt。 Ltd.（印度）和 Baxter（美國）。
市場開發
- 2019年11月，諾華公司宣布與美國製藥公司Medicines Company達成策略協議。該公司達成的這項協議增強了其創新藥物產品組合，從而增加了市場銷售和收入
- 2020年8月，Jubilant Pharma Limited宣布推出其名為JUBI-R的產品，即用於治療COVID-19的注射用瑞德西韋。該公司在 COVID-19 疫情艱難時期推出的這款產品，提高了其在市場上的信譽和需求
- 2020年7月，Fondaco Pte Ltd宣布，由於潛在品質問題，已在零售層級召回其名為euronox 注射用凍乾粉100單位/瓶的產品。該公司此次召回產品的行為降低了其在市場上的信譽，導致其產品在市場上的需求下降
- 2019年1月，太陽製藥工業公司（Sun Pharmaceutical Industries Inc.）宣布，其全資子公司太陽製藥工業有限公司（Sun Pharmaceutical Industries, Ltd）宣布自願召回三批註射用維庫溴銨10毫克、20毫克（凍乾粉）和注射液至醫院層面，原因是其中含有玻璃。該公司此次召回產品的行為降低了其在市場上的信譽，導致其產品在市場上的需求下降
區域分析
從地理上看，市場報告涵蓋的國家有：北美洲的美國、加拿大和墨西哥、歐洲的德國、法國、英國、荷蘭、瑞士、比利時、俄羅斯、義大利、西班牙、土耳其、歐洲其他地區、中國、日本、印度、韓國、新加坡、馬來西亞、澳洲、泰國、印尼、菲律賓、亞太地區（APAC）的其他地區、沙烏地阿拉伯、阿聯酋、南非、澳洲、其他國家的歐洲、歐洲、歐洲地區和其他國家的歐洲地區（歐洲地區的歐洲國家。
根據 Data Bridge 市場研究分析：
2021 年至 2028 年預測期內，北美是冷凍乾燥注射藥物 市場的主導地區
- 2021 年，由於主要市場參與者的存在和技術進步的加快，北美在冷凍乾燥注射藥物市場佔據主導地位。
預計2021 年至 2028 年預測期內，亞太地區將成為冷凍乾燥注射藥物 市場成長最快的地區
在預測期內，預計亞太地區將成為發展最快的地區，因為各種疾病對冷凍乾燥藥物的需求不斷增加，藥物測試的研發實驗室也在增加。
新冠肺炎疫情的影響
目前正在進行研究，以確定凍乾的新型治療藥物對住院成年 COVID-19 患者的治療效果和安全性。在此之中，醫療保健行業的主要參與者、製藥巨頭西普拉（Cipla）因推出其註射用CIPREMI瑞德西韋凍乾粉（100毫克）而受到讚譽。為了提高美國 FDA 批准的緊急使用授權 (EUA) 藥物對嚴重 COVID-19 症狀患者的可及性，冷凍乾燥注射劑市場的製造商正在從這些進步中汲取靈感。
有關凍乾注射藥物市場 報告的更多詳細信息，請單擊此處 - https://www.databridgemarketresearch.com/reports/global-lyophilized-injectable-drugs-market
